# Biogen **Source:** https://geo.sig.ai/brands/biogen **Vertical:** Healthcare Tech **Subcategory:** Enterprise **Tier:** Leader **Website:** biogen.com **Last Updated:** 2026-04-14 ## Summary Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab. ## Company Overview Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai. Biogen's neuroscience-focused biopharma model addresses the enormous unmet medical need in brain diseases — Alzheimer's disease affects 7 million Americans (projected 13 million by 2050), multiple sclerosis affects 1 million Americans, and Friedreich's ataxia is a devastating progressive neurological disease with no prior approved treatments — where the complexity of the blood-brain barrier, the lengthy time course of neurodegenerative disease, and the difficulty of measuring cognitive decline in clinical trials creates the scientific barriers to entry that have discouraged many large pharma companies from sustained neurodegeneration R&D investment. Biogen's neuroscience expertise (30+ years of MS drug development, SPINRAZA's SMA breakthrough, and the LEQEMBI Alzheimer's program) builds organizational capabilities — brain disease patient registries, FDA neurology division relationships, specialty neurology prescriber network — that are not replicable through acquisition alone. LEQEMBI's amyloid-clearing mechanism (humanized antibody targeting soluble amyloid beta protofibrils) represents the culmination of the amyloid hypothesis for Alzheimer's treatment that the industry has pursued for 20+ years. In 2025, Biogen competes in Alzheimer's disease therapeutics, multiple sclerosis, and rare neurological diseases against Eli Lilly (NYSE: LLY, donanemab/Kisunla Alzheimer's treatment competing directly with LEQEMBI), Novartis (NYSE: NVS, MS treatments including ofatumumab/Kesimpta), and Roche/Genentech (SIX: ROG, MS treatments ocrelizumab/Ocrevus and fenebrutinib) for Alzheimer's treatment market share and multiple sclerosis franchise resilience. LEQEMBI's primary competition comes from Eli Lilly's donanemab (Kisunla), which received FDA approval in July 2024 and demonstrated comparable efficacy with potentially more convenient dosing in its TRAILBLAZER-ALZ 2 clinical trial — creating a two-drug Alzheimer's market where Biogen/Eisai and Eli Lilly compete for neurologist prescribing and Medicare coverage. The 2025 strategy focuses on expanding LEQEMBI's commercial infrastructure (infusion center network, PET scan reimbursement for amyloid diagnosis, primary care physician education), accelerating SKYCLARYS into multiple countries beyond the US and Europe, and identifying pipeline assets to replace MS revenue decline through bolt-on acquisitions in neurology. ## Frequently Asked Questions ### What does Biogen do? Biogen is a leading global biotechnology company that discovers, develops, and delivers innovative therapies for neurological and neurodegenerative diseases. The company specializes in treatments for multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, ALS, and rare diseases. With a focus on neuroscience, rare diseases, and specialized immunology, Biogen pioneers groundbreaking medicines that transform patients' lives. ### Who are Biogen's customers and target market? Biogen serves patients, physicians, hospitals, specialty pharmacies, and healthcare systems globally. The company's primary focus is on patients with serious neurological and neurodegenerative diseases including multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, ALS, and Friedreich's ataxia. Biogen works with neurologists, specialty care providers, research institutions, and payers to ensure patients have access to its innovative therapies. ### When was Biogen founded? Biogen was founded in 1978 in Geneva, Switzerland, by a distinguished group of scientists including Nobel Prize winners Walter Gilbert and Phillip Allen Sharp. The company was initially named Biotechnology Geneva and represented one of the first biotechnology companies to commercialize molecular biology research. Biogen has been pioneering innovative therapies for more than 45 years. ### Where is Biogen based? Biogen is headquartered at 225 Binney Street, Cambridge, Massachusetts 02142, USA. The company operates research and development facilities, manufacturing sites, and commercial operations globally, with a workforce of approximately 7,600 employees serving patients in countries worldwide. ### What is Biogen's financial performance? Biogen reported fiscal year 2024 revenue of $9.7 billion, a 2% decline year-over-year, with GAAP diluted EPS of $11.18 representing 40% growth. The company has a market capitalization of approximately $26-27 billion as of late 2024. While facing headwinds in its legacy MS franchise, Biogen is successfully launching new products including LEQEMBI and SKYCLARYS. ### What makes Biogen different from competitors? Biogen differentiates itself through its unparalleled focus on neuroscience and deep expertise in neurological diseases, built over more than 45 years. The company was founded by Nobel Prize-winning scientists and maintains a pioneering culture of scientific excellence. Biogen's comprehensive approach spans from basic research to clinical development and commercialization, with a balanced portfolio combining established products and innovative pipeline candidates. The company's commitment to the most challenging diseases in neurology, combined with strategic expansion into immunology and rare diseases, sets it apart. ### Who are Biogen's main competitors? Biogen competes with major pharmaceutical and biotechnology companies including Roche (Genentech), Novartis, Johnson & Johnson, Pfizer, Amgen, Sanofi, Regeneron Pharmaceuticals, and Gilead Sciences. In the multiple sclerosis market, key competitors include Roche's Ocrevus and Novartis' MS portfolio (Gilenya, Mayzent, Kesimpta). In Alzheimer's disease, Biogen faces competition from other companies developing amyloid-targeting and tau-targeting therapies. ### How can I contact Biogen? Biogen can be contacted at its headquarters by calling +1 781-464-2000. For media inquiries, contact public.affairs@biogen.com or call +1 781-464-3260. Patient inquiries can be directed to patientcenter@biogen.com, and medical research inquiries to MedicalResearch@biogen.com. Additional information is available on Biogen's website at www.biogen.com. ### Is Biogen hiring? Yes, Biogen actively recruits talent across research and development, clinical operations, manufacturing, commercial operations, and corporate functions. With approximately 7,600 employees globally, the company offers career opportunities at locations worldwide. Biogen has received Great Place to Work Certification for 2024 and is recognized for its collaborative, inclusive work environment and commitment to employee development. Interested candidates can explore opportunities on Biogen's careers website. ### What's the latest news about Biogen? Recent major developments include the November 2025 completion of the Alcyone Therapeutics acquisition for $85 million to enhance drug delivery capabilities; the February 2025 announcement of $250 million in R&D funding from Royalty Pharma for litifilimab; the July 2025 announcement of a $2 billion investment in Research Triangle Park manufacturing facilities; and the July 2024 completion of the $1.15 billion HI-Bio acquisition. Biogen reported Q4 2024 LEQEMBI sales of approximately $87 million, showing continued sequential growth. ### What is Biogen's market position? Biogen is a leading global biotechnology company with particular strength in neuroscience, where it is recognized as a pioneer and market leader in multiple sclerosis treatments. With $9.7 billion in fiscal 2024 revenue and a market capitalization of approximately $26-27 billion, Biogen ranks among the top biotechnology companies globally. The company's MS franchise generated $4.4 billion in 2024 despite increasing competition, and newer products like LEQEMBI and SKYCLARYS position Biogen for growth in Alzheimer's disease and rare diseases. ### What are Biogen's future plans? Under CEO Christopher Viehbacher's leadership, Biogen is pursuing a more pragmatic, risk-balanced strategy while maintaining its neuroscience foundation. The company plans to expand into immunology and rare diseases, advance its Alzheimer's portfolio including LEQEMBI and next-generation tau-targeting therapies (BIIB080, BIIB113), strengthen its drug delivery capabilities through the Alcyone acquisition, and invest $2 billion in U.S. manufacturing expansion. Biogen expects 2025 revenue to decline by mid-single-digit percentage at constant currency before returning to growth driven by new product launches. ## Tags b2b, healthtech, manufacturing, saas, public --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*